Protagonist Therapeutics, Inc.

Total Valuation

Protagonist Therapeutics, Inc. carries a market capitalization of 8.70B, placing it among publicly traded companies globally. Its enterprise value stands at 7.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Protagonist Therapeutics, Inc. currently has 64.67M shares outstanding.

Valuation Ratios

Protagonist Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 95.67. The price-to-sales ratio is 28.13, and the price-to-book ratio stands at 9.42.

Enterprise Valuation

On an enterprise value basis, Protagonist Therapeutics, Inc. trades at an EV/EBITDA multiple of 119.47 and an EV/FCF ratio of 54.28. The EV/Sales ratio of 25.37 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 122.62 provides insight into valuation relative to core operating earnings.

Financial Position

Protagonist Therapeutics, Inc. maintains a current ratio of 21.71, meaning it holds 21.7x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Protagonist Therapeutics, Inc. posts a return on equity of 10.98 and a return on invested capital of 7.50.

Taxes

Over the trailing twelve months, Protagonist Therapeutics, Inc. has paid 1.43M in income taxes, reflecting an effective tax rate of 1.69.

Stock Price Statistics

Protagonist Therapeutics, Inc.'s stock has gained approximately 75.23462% over the past 52 weeks. The 50-day moving average sits at 145.16, while the 200-day moving average is 114.00.

Income Statement

Over the trailing twelve months, Protagonist Therapeutics, Inc. generated 281.99M in revenue and converted that into 82.91M in net income, yielding earnings per share of 1.23. EBITDA reached 59.88M, while operating income came in at 58.34M.

Balance Sheet

Protagonist Therapeutics, Inc. holds 782.58M in cash and equivalents against 9.22M in total debt, resulting in a net debt position of -420.08M. Total book value stands at 841.54M, with working capital of 769.97M providing operational flexibility.

Cash Flow

Protagonist Therapeutics, Inc. produced 131.20M in operating cash flow over the past twelve months. After subtracting -615,000.00 in capital expenditures, free cash flow totaled 130.58M - equivalent to 2.02 per share.

Margins

Protagonist Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 20.69 and net profit margin of 29.40 provide insight into operational efficiency.

Dividends & Yields

Scores

Protagonist Therapeutics, Inc. posts an Altman Z-Score of 109.20, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.